Literature DB >> 15801568

Assessing internal tobacco industry knowledge of the neurobiology of tobacco dependence.

Geoffrey Ferris Wayne1, Gregory N Connolly, Jack E Henningfield.   

Abstract

The recent availability of internal tobacco industry documents provides a significant resource for evaluating industry understanding of the pharmacological, psychosocial, and behavioral mechanisms underlying tobacco dependence. In this study, we catalog the range of efforts undertaken by tobacco manufacturers seeking knowledge of these mechanisms. Some areas of industry research, such as cellular and molecular studies of nicotine and its effects, are widely available in the open literature. Of greater interest are internal research projects that have demonstrated direct influence on product development. These include studies of smoker psychology and behavior, evoked-response studies of tobacco-delivered nicotine, the effects of sensory perception, dose-related effects, and the development of nicotine analogs and synergists. Our findings suggest extensive industry knowledge of mechanisms that determine smoker perception and behavior, and application of this knowledge in product development, including control of sensory response, uptake of nicotine, and product effects. Independent research recently has begun to consider the contributions of tobacco product ingredients and design factors to the determination of risk, severity, and prevalence of addiction. However, the application of these findings to cessation and treatment efforts is still quite limited. We conclude that clinical research would greatly benefit from further examination of the decades of knowledge accumulated by tobacco manufacturers.

Entities:  

Mesh:

Year:  2004        PMID: 15801568     DOI: 10.1080/14622200412331324839

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  15 in total

1.  Smokers' self-reported responses to the introduction of reduced ignition propensity (RIP) cigarettes.

Authors:  Andrew B Seidenberg; Vaughan W Rees; Hillel R Alpert; Richard J O'Connor; Gary A Giovino; Andrew Hyland; Gregory N Connolly
Journal:  Tob Control       Date:  2011-07-12       Impact factor: 7.552

Review 2.  Nicotine reduction revisited: science and future directions.

Authors:  Dorothy K Hatsukami; Kenneth A Perkins; Mark G Lesage; David L Ashley; Jack E Henningfield; Neal L Benowitz; Cathy L Backinger; Mitch Zeller
Journal:  Tob Control       Date:  2010-10       Impact factor: 7.552

3.  Nicotine psychopharmacology research: advancing science, public health, and global policy.

Authors:  Jack E Henningfield; Ian P Stolerman; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2006-03       Impact factor: 4.530

4.  Smoking normalizes cerebral blood flow and oxygen consumption after 12-hour abstention.

Authors:  Manouchehr S Vafaee; Albert Gjedde; Nasrin Imamirad; Kim Vang; Mallar M Chakravarty; Jason P Lerch; Paul Cumming
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-31       Impact factor: 6.200

5.  Conference on abuse liability and appeal of tobacco products: conclusions and recommendations.

Authors:  Jack E Henningfield; Dorothy K Hatsukami; Mitch Zeller; Ellen Peters
Journal:  Drug Alcohol Depend       Date:  2011-03-03       Impact factor: 4.492

6.  'To prove this is the industry's best hope': big tobacco's support of research on the genetics of nicotine addiction.

Authors:  Kenneth R Gundle; Molly J Dingel; Barbara A Koenig
Journal:  Addiction       Date:  2010-06       Impact factor: 6.526

Review 7.  Tobacco industry litigation position on addiction: continued dependence on past views.

Authors:  Jack E Henningfield; Christine A Rose; Mitch Zeller
Journal:  Tob Control       Date:  2006-12       Impact factor: 7.552

Review 8.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 9.  Assessing consumer responses to potential reduced-exposure tobacco products: a review of tobacco industry and independent research methods.

Authors:  Vaughan W Rees; Jennifer M Kreslake; K Michael Cummings; Richard J O'Connor; Dorothy K Hatsukami; Mark Parascandola; Peter G Shields; Gregory N Connolly
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 10.  Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy.

Authors:  Jack E Henningfield; Saul Shiffman; Stuart G Ferguson; Ellen R Gritz
Journal:  Pharmacol Ther       Date:  2009-04-08       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.